- Home
- VERV vs RIG Comparison
VERV vs RIG Comparison
Compare VERV & RIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERV
- RIG
- Stock Information
- Founded
- VERV 2018
- RIG 1926
- Country
- VERV United States
- RIG Switzerland
- Employees
- VERV N/A
- RIG N/A
- Industry
- VERV Medicinal Chemicals and Botanical Products
- RIG Oil & Gas Production
- Sector
- VERV Health Care
- RIG Energy
- Exchange
- VERV Nasdaq
- RIG Nasdaq
- Market Cap
- VERV 384.2M
- RIG N/A
- IPO Year
- VERV 2021
- RIG 1993
- Fundamental
- Price
- VERV $4.45
- RIG $2.49
- Analyst Decision
- VERV Strong Buy
- RIG Hold
- Analyst Count
- VERV 6
- RIG 8
- Target Price
- VERV $25.75
- RIG $4.29
- AVG Volume (30 Days)
- VERV 2.9M
- RIG 36.9M
- Earning Date
- VERV 05-14-2025
- RIG 07-30-2025
- Dividend Yield
- VERV N/A
- RIG N/A
- EPS Growth
- VERV N/A
- RIG N/A
- EPS
- VERV N/A
- RIG N/A
- Revenue
- VERV $59,613,000.00
- RIG $3,667,000,000.00
- Revenue This Year
- VERV $6.18
- RIG $10.36
- Revenue Next Year
- VERV N/A
- RIG N/A
- P/E Ratio
- VERV N/A
- RIG N/A
- Revenue Growth
- VERV 271.44
- RIG 24.47
- 52 Week Low
- VERV $2.87
- RIG $1.97
- 52 Week High
- VERV $9.31
- RIG $6.25
- Technical
- Relative Strength Index (RSI)
- VERV 47.78
- RIG 48.17
- Support Level
- VERV $3.89
- RIG $2.51
- Resistance Level
- VERV $4.63
- RIG $2.66
- Average True Range (ATR)
- VERV 0.41
- RIG 0.12
- MACD
- VERV 0.02
- RIG 0.00
- Stochastic Oscillator
- VERV 47.06
- RIG 27.78
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.